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Background: Microglia and macrophages play a central role in neuroinflammation. Pro-inflammatory cytokines
trigger their conversion to a classically activated (M1) phenotype, sustaining inflammation and producing a
cytotoxic environment. Conversely, anti-inflammatory cytokines polarize the cells towards an alternatively activated
(M2), tissue reparative phenotype. Elucidation of the signal transduction pathways involved in M1 to M2 phenotypic
conversion may provide insight into how the innate immune response can be harnessed during distinct phases of
disease or injury to mediate neuroprotection and neurorepair.
Methods: Microglial cells (cell line and primary) were subjected to combined cyclic adenosine monophosphate
(cyclic AMP) and IL-4, or either alone, in the presence of pro-inflammatory mediators, lipopolysaccharide (LPS), or
tumor necrosis factor-α (TNF-α). Their effects on the expression of characteristic markers for M1 and M2 microglia
were assessed. Similarly, the M1 and M2 phenotypes of microglia and macrophages within the lesion site were
then evaluated following a contusive spinal cord injury (SCI) to the thoracic (T8) spinal cord of rats and mice when
the agents were administered systemically.
Results: It was demonstrated that cyclic AMP functions synergistically with IL-4 to promote M1 to M2 conversion
of microglia in culture. The combination of cyclic AMP and IL-4, but neither alone, induced an Arg-1+/iNOS−cell
phenotype with concomitant expression of other M2-specific markers including TG2 and RELM-α. M2-converted
microglia showed ameliorated production of pro-inflammatory cytokines (TNF-α and IP-10) and reactive oxygen
species, with no alteration in phagocytic properties. M2a conversion required protein kinase A (PKA), but not the
exchange protein directly activated by cyclic AMP (EPAC). Systemic delivery of cyclic AMP and IL-4 after experimental
SCI also promoted a significant M1 to M2a phenotypic change in microglia and macrophage population dynamics in
the lesion.
Conclusions: Using primary microglia, microglial cell lines, and experimental models of CNS injury, we demonstrate
that cyclic AMP levels are a critical determinant in M1–M2 polarization. High levels of cyclic AMP promoted an Arg-1+
M2a phenotype when microglia were activated with pro-inflammatory stimuli and Th2 cytokines. Th2 cytokines or
cyclic AMP independently did not promote these changes. Phenotypic conversion of microglia provides a powerful
new therapeutic approach for altering the balance of cytotoxic to reparative microglia in a diversity of neurological
diseases and injury.
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CNS resident microglia and infiltrating macrophages play
a pivotal role in the acute inflammatory response to
neurological injury and disease [1], altering the lesion
environment to either a cytotoxic milieu characterized by
ongoing tissue damage and cell death [2] or a reparative
environment, defined by extracellular matrix remodeling,
angiogenesis, and axonal regrowth [3]. The functions of
these cells and their immunophenotypical characteristics
are governed by a variety of signals produced both system-
ically and at the site of tissue injury, which drive them
from a resting state to either a “classically activated,” pro-
inflammatory M1 phenotype or an “alternatively acti-
vated,” reparative M2 phenotype [4]. Activators of the M1
phenotype, tumor necrosis factor-α (TNF-α), and
interferon-γ (IFN-γ), induce microglia to produce pro-
inflammatory cytokines, oxidative metabolites, and prote-
ases [5], which although important for microbial defense
[6], exacerbate the extent of the initial neural injury and
associated dysfunction [7]. Markers of the M1 phenotype
include inducible nitric oxide (iNOS), cyclo-oxygenase-2
(COX-2), and cell surface markers such as CD16, CD86,
and MHC II. Conversely, the M2 phenotype results from
microglial activation in the presence of anti-inflammatory
cytokines, including interleukin (IL)-4, IL-10, IL-13, and
tumor growth factor-β (TGF-β) [8]. M2 microglia produce
a variety of growth factors including vascular endothelial
growth factor (VEGF), brain-derived neurotrophic factor
(BDNF), and platelet-derived growth factor (PDGF), which
are important for promoting angiogenesis, oligodendro-
cyte maturation, axonal regrowth, and remyelination re-
pair that is conducive to wound healing [9]. The M2a
phenotype, a subset of the alternatively activated state of
microglia or macrophages, is characterized by the markers
Arginase-1 (Arg-1), transglutaminase-2, RELM-α, and
YM1 [8, 9].
Though studies have suggested that the presence of
Th2 cytokines alone are sufficient for converting a pro-
inflammatory, activated M1 form to an M2a phenotype,
a persistent M1–M2a conversion using this approach
has not been achievable in vivo; macrophages that have
been stimulated towards this alternatively activated
phenotype by Th2 cytokines alone are unable to retain
their immunophenotypical and functional properties
when placed within the injured or diseased CNS milieu,
reverting instead to the M1 phenotype [10]. In the
current study, we have demonstrated that cyclic adeno-
sine monophosphate (cyclic AMP) levels are a critical
determinant in pronounced M1 to M2a phenotype con-
version when microglial cells are in the presence of pro-
and anti-inflammatory stimuli. The elevation of cyclic
AMP in microglia or macrophages, through the use of
adenylyl cyclase (AC) activators, phosphodiesterase
(PDE) inhibitors, synthetic cyclic AMP analogs, or β-adrenergic receptor agonists, inhibits the production of
pro-inflammatory genes [11] that are controlled by the
master immune regulator, transcription factor nuclear
factor kappa B (NF-κB; [12]). We suggest that the role of
cyclic AMP signaling is to suppress the M1 phenotype,
largely by inhibiting NF-κB, thus potentiating the alter-
native activation of microglia into an augmented, M2a




Cytokines were purchased from PeproTech (Rocky
Hills, NJ). Cyclic AMP analogs were obtained from the
BIOLOG Life Science Institute (Bremen, Germany) ex-
cept dioctynyl cyclic AMP, which was obtained from
Santa Cruz Biotechnology Inc. (Dallas, TX). Lipopoly-
saccharide (LPS) was purchased from Sigma-Aldrich
(St. Louis, MO).
BV2 microglial cell culture
The immortalized BV2 microglial cell line employed for
in vitro experiments was derived from the C57BL/6
mouse [13] and exhibits phenotypic and functional prop-
erties of primary microglia [14]. BV2 microglia were cul-
tured at 37 °C, 5 % CO2 in Dulbecco’s modified Eagle’s
medium (DMEM; Gibco, Life Technologies Corporation,
Grand Island, NY) supplemented with 10 % heat-
inactivated fetal bovine serum (FBS; HyClone, Logan, UT)
and 100 units/mL each of penicillin and streptomycin
(Sigma-Aldrich). Prior to experimental use, BV2 microglia
were seeded on either six-well culture plates (5 × 104 cells/
well for biochemistry experiments) or eight-well chamber
slides (5 × 103 cells/well for immunocytochemistry) and
grown to 70–80 % for experimental use. BV2 microglia
were treated with various cytokines or pharmacological
agents based on the experimental schema described
below.
Primary microglial cell culture
Primary cultures of microglia were prepared from the
cerebral cortex of neonatal (P1) wild type C57Bl/6J
mice (JAX® Mice and Services, Bar Harbor, ME) using
previously published methods [15]. Briefly, the cerebral
cortices were dissected and cut into 2-mm small pieces.
Tissue was suspended in cold DMEM (Gibco, Life
Technologies Corporation) and triturated using a P-
1000 plastic tip. The resulting cell suspension was
passed through a 100-μm cell strainer and then centri-
fuged at ×1000 rpm for 10 min. The supernatant was
removed and the pellet re-suspended in DMEM con-
taining 10 % FBS and 10 % horse serum (Gibco, Life
Technologies Corporation). The cell suspension was
plated on polylysine (PLL)-coated T75 flasks and
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then placed on an orbital shaker at X230 rpm for 3 h, and
the media, containing detached microglia, was harvested.
Following centrifugation for 10 min at ×1000 rpm, a pellet
containing the microglial cell fraction was acquired and
re-suspended in the same media as described above.
Highly pure microglial cell cultures were obtained using
this method (>95 % as assessed using immunocytochem-
istry for CD11b (AbD Serotec; Raleigh, NC) and iba1
(Wako Pure Chemicals; Richmond, VA)). Primary micro-
glia were diluted to the desired cell concentration and
plated for at least 24 h before experimental use.
M1 to M2 phenotypic conversion
M1 activation was achieved with LPS (100 ng/ml) or
TNF-α (10 ng/mL). For M1 to M2a phenotype conver-
sion, IL-4 (10 ng/mL) was used in combination with
cyclic AMP analogs (dibutyryl cyclic AMP; (1 mM), 6-
Phe-cyclic AMP; (100 μM), CPT-2′O cyclic AMP;
(100 μM)) beginning at 15 min prior to M1 activation.
Cell supernatants were analyzed for cytokine levels, cell
lysates prepared, or the cells fixed with 4 % paraformal-
dehyde 24 h later to measure the expression of M1 and
M2a phenotype markers. All data are representative of
at least three independent experiments.
Assessment of phagocytic function
Phagocytic function was evaluated based on the uptake of
phycoerythrin (PE)-conjugated latex beads (Phagocytosis
Assay Kit; Cayman Chemical, Ann Arbor, MI) as per the
manufacturer’s protocol. Percent phagocytic cells was
quantified in relation to the total number of Hoechst-
positive nuclei in four random fields per treatment well
and averaged across five independent experiments by
fluorescence microscopy.
Western blotting
Immunoblotting was performed on culture supernatants,
total cell lysates, or spinal cord (T7–9) tissue homoge-
nates to quantify the expression of M1 and M2a markers
according to previously published methods [15]. Nitro-
cellulose membranes (Bio-Rad Laboratories) were
probed with specific primary antibodies; Arg-1 (1:2,000;
GeneTex Inc., Irvine, CA), iNOS (1:1,000; Cell Signaling
Technology, Boston, MA), TNF-α (1:500; Life Technolo-
gies Corp.), and β-actin (Sigma-Aldrich). The optical
density of the bands (arbitrary units) was measured with
an imaging densitometer (Bio-Rad Laboratories) and
normalized to β-actin levels. The data represents values
from three independent experiments.
ELISA
Levels of the pro-inflammatory cytokines in culture su-
pernatants was quantified using mouse TNF-α, IP-10,and IL-1β enzyme-linked immunosorbent assays (ELISA;
Pepro Tech, Rocky Hill, NJ) according to the manufac-
turer's protocols. Values were obtained as picogram per
milliliter of the culture supernatant and expressed as ab-
solute values and compared between each of the treat-
ment conditions. The data presented are the mean ±
SEM of four independent experiments.
Determination of reactive oxygen species
The presence of reactive oxygen species (ROS) was mea-
sured using the non-fluorescent dye 2′,7′-dichlorofluores-
cein diacetate (DCFH-DA; Molecular Probes, Eugene,
OR) as per the manufacturer’s instructions. DCF fluores-
cence measurements were made in 96-well plates using a
SpectraMax 5 microplate reader at 485 nm for excitation
and 530 nm for emission. The data obtained were repre-
sentative of three independently conducted experiments.
Nitrite assay
Microglia nitrite production was assessed by measuring
total nitrite concentration, a stable oxidation product of
NO by the Griess reaction. Briefly, culture supernatants
(50 μl) were mixed with an equal volume of Griess re-
agent (Life Technologies Corp.) in 96-well plates for
10 min at room temperature in the dark, and the ab-
sorbance at 570 nm was determined using a SpectraMax
5 microplate reader. Sodium nitrite at concentrations of
0 to 100 μM was used as a standard. Each value indi-
cates the mean ± SEM and is representative of results
obtained from three independent experiments.
Immunocytochemistry
M1 and M2 marker expression in microglia was examined
using immunocytochemistry (ICC) according to previ-
ously published methods [15]. Fixed cells were probed
with primary antibodies for the M1 phenotype, iNOS
(1:200; BD Transduction Laboratories; Franklin Lakes,
NJ), and COX-2 (1:200; Thermo Scientific, Rockford, IL)
or the M2 phenotype, Arg-1 (1:200; GeneTex, Irvine, CA),
RELMα/Fizz1 (1:100; PeproTech, Rocky Hill, NJ), or
transglutaminase-2 (1:100; Thermo Fischer Scientific). In
addition, the microglial cell markers anti-iba1 (1:5,000;
Wako Pure Chemical Industries, Ltd., Tokyo, Japan) and
CD68/ED1 (Macrosialin; 1:200; AbD Serotec) were used.
For visualization, the secondary antibodies, goat anti-
mouse Alexa-594 or anti-rabbit Alexa-594 (1:200, Life
Technologies Corp.) were used along with the nuclear
marker Hoechst 33342 (1:1,000; Life Technologies Corp.).
The morphology of the cells was demarcated by staining
with Phalloidin-488 (1:100; Life Technologies Corp). Im-
ages were acquired by sequential scanning of the immu-
nostained cells with an Olympus Fluorescence confocal
microscope (Olympus, Fluoview FV 1000). For each treat-
ment condition, three to four randomly selected fields
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tive of three independently conducted experiments.
Imaging and analysis
Confocal images were acquired by sequential scanning
of the immunostained cells with an Olympus Fluores-
cence Microscope (Olympus, FluoView FV1000) at laser
lines based on the specific Alexa-fluor secondaries used.
In Adobe Photoshop CS6 (Adobe Systems, San Jose,
CA) fluorescent images had the same universal adjust-
ments applied: brightness (+50), contrast (+30), and
smart sharpen (1.0 pixels).
Measurement of fluorescent intensity per cell
The per cell immunostaining fluorescence intensity of
specific markers was quantified using Image J software
(http://imagej.nih.gov/ij/). For each treatment condition,
randomly selected cells [10, 11] per well/plate from
independent experiments were identified by Hoechst-
positive nuclei and imaged. These images were con-
verted to grayscale, and the average per pixel intensity of
the signal per cell (arbitrary units (a.u.) was recorded
after background subtraction. These measurements were
averaged across the cells analyzed per plate and then
among group replicates for comparison of signal change
across treatments.
Spinal cord contusion injury
Two models of spinal cord injury (SCI) were used in this
study to examine the effects of IL4 and db-cyclic AMP
on microglia and macrophage phenotypes in rodents.
The first model employed adult Lewis rats (female, 180–
200 g, n = 3), the second C57BL/6 (female, 25 g) mice
(both from Charles River Laboratories International Inc.,
Wilmington, MA). Animals were housed according to
NIH guidelines and The Guide for the Care and Use of
Animals. All animal procedures were approved by the
University of Miami Institutional Animal Care and Use
Committee (IACUC). The rats were subjected to a mod-
erate (25.0 mm) thoracic (T8) spinal cord contusion
induced by the MASCIS weight drop device developed
at New York University [16] as described previously
[17]. For the mouse model (n = 3 per group) animals
were subjected to a 50 kdyne moderate spinal cord contu-
sion at thoracic (T8) level using the Infinite Horizons (IH)
impactor as described previously [18]. Post-operative care
was provided as described in Patel et al. [19].
Administration of M2a converting agents
With the Lewis rat model, IL-4 and db-cyclic AMP were
delivered by intravenous (i.v.) administration through a
jugular vein catheter prepared as described previously
[20]. A mix of db-cyclic AMP (50 mg/kg) and IL-4
(30 μg/kg) in 100 μl of sterile, deionized water wasadministered as a single bolus injection with a 0.5-ml
tuberculin syringe attached to the i.v. catheter over a
period of 2 min within 15 min of SCI, followed by a
250-μl physiological saline flush. For the mouse model,
the animals received daily, intraperitoneal injections
(100 μl) of the agents at the same concentrations begin-
ning at 30 min post-SCI for 7 days until end-point.Animal perfusion and tissue extraction
Animals were deeply anesthetized (150 mg/kg ketamine,
10 mg/kg xylazine) and transcardially perfused and the
extracted CNS tissue post-fixed and cryoprotected as de-
scribed elsewhere [21]. The T7–9 spinal cord was cryo-
sectioned at a thickness of 20 μm (coronal) on a Leica
CM3050S Cryostat (Leica Microsystems Inc., Buffalo
Grove, IL). For biochemistry, animals were deeply anes-
thetized at 24 h post-SCI and decapitated. A spinal cord
segment (5 mm) encompassing the injury epicenter dis-
sected and snap frozen in liquid nitrogen for storage at
−80 °C until processed for analysis.Immunohistochemistry
Coronal, 20-μm cryosectioned sections of injured spinal
cord tissue (400-μm intervals) were immunohistochemi-
cally (IHC) stained for specific markers using methods as
described elsewhere [20]. For IHC, the Arg-1 antibody
(1:200) was combined with anti-CD68 (ED1; 1:200; AbD
Serotec), Alexa-594 tagged Isolectin-IB4 (1:100; Life Tech-
nologies Corp.) or anti-iba1 (1:5,000; Wako) along with
appropriate AlexaFluor conjugated secondary antibodies
(1:200; Life Technologies Corp.) and Hoechst 33342
(Sigma-Aldrich).Quantification of microglial cells at the lesion site
For quantifying the conversion of microglia and macro-
phages to M2a, cells displaying double immunoreactivity
for Arginase-1 (Alexa-488 secondary antibody) and
Alexa-594-tagged Isolectin-IB4 were quantified from
projection images obtained using a confocal microscope
(Olympus, Fluoview 1000) at ×40 magnification. These
images were taken from within the injury epicenter, from
the dorsal funiculus region of the spinal cord (n = 3 mice
per group of IL-4 and db-cyclic AMP-treated and SCI-
only controls). Images were converted to 8-bit gray scale
separately for each marker using Image J software, and a
threshold value was obtained. The relative percent of
cells that were displaying the M2a phenotype were ana-
lyzed by measuring the fluorescent intensity of the num-
ber of cells showing Arginase-1 immunoreactivity and
the total number of Isolectin-IB4+ cells between the
treated and the untreated groups.
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Significant differences between groups were ascertained
by a one-way analysis of variance (ANOVA) or a t test,
followed by a Bonferroni post-hoc analysis using Graph
Pad Prism 4.0 (Graphpad Software, La Jolla, CA). All data
was analyzed at the 95 % confidence interval. Graphed
data was expressed as the mean ± standard error of the
mean (SEM) according to the number of replicates or
independent experiments. Asterisks or hashes included on
the graphs indicate statistical differences between the
treatment and control condition(s) with significance indi-
cated at ***/###p < 0.001, **/##p < 0.01, or */#p < 0.05.
Results
Cyclic AMP and IL-4 synergize to augment expression of
M2a phenotypic markers in microglia induced to an M1
form by pro-inflammatory mediators
BV2 microglia exposed to a pro-inflammatory stimulus,
LPS, showed M1 phenotype induction as evidenced by
pronounced expression of the characteristic markers
iNOS and COX-2 and an absence of the M2a markers,
Arginase-1, transglutaminase-2, and RELM-α (Fig. 1a–
e). Concurrent treatment of LPS-stimulated BV2 micro-
glia with IL4 and db-cyclic AMP but, neither independ-
ently (data not shown), antagonized M1 marker
expression while dramatically augmenting an M2a
phenotype as demonstrated by robust expression of M2a
markers (Fig. 1f–j). M1 to M2a phenotype conversion in
BV2 microglia was demonstrated immunocytochemically
also with another pro-inflammatory mediator, TNF-α, in
which, compared to untreated (Fig. 1k–l) or TNF-α-
stimulated controls (Fig. 1m, n), combined IL-4 and db-
cyclic AMP induced robust Arginase-1 production and
the antagonism of iNOS expression (Fig. 1s, t). Only
minor changes in Arginase-1 and iNOS were observed
in TNF-α-stimulated BV2 microglia treated with IL-4
(Fig. 1o–p) or db-cyclic AMP (Fig. 1q–r) independently
at the doses employed. Similarly, modest expression of
transglutaminase-2, and RELM-α were detected with IL-
4 treatment, but the presence of db-cyclic AMP dramat-
ically potentiated their expression and the alternatively
activated M2a phenotype (data not shown).
The necessity of cyclic AMP for robust M1 to M2
phenotype conversion was further demonstrated bio-
chemically by immunoblotting for the prototypical M2
marker Arginase-1 (Fig. 1u, v). In unstimulated, resting
microglia (M0 phenotype), exposure to IL-4 alone, but
not db-cyclic AMP, elevated levels of Arginase-1, indica-
tive of a transition to an M2 phenotype. However, as
observed with LPS- or TNF-α-induced M1 microglia,
exposure of the resting M0 microglia to the combination
of IL-4 and db-cyclic AMP showed a much more pro-
nounced expression of Arginase-1 (3.6-fold higher, p <
0.001). In M1 activated microglia exposed to either LPSor TNF-α, IL-4 and db-cAMP when given independently
at the dose used did not induce robust Arginase-1 com-
pared to concurrent application of IL-4 and db-cyclic
AMP (Fig. 1u, v).
To examine the dose-dependent effects of IL-4 and
db-cyclic AMP on the phenotype conversion of M1
microglia (iNOS+) to M2 phenotype (Arginase-1+), im-
munoblotting studies with titrated concentrations of
these agents were performed. When the concentration
of db-cyclic AMP was kept constant at 1 mM, IL-4 con-
centrations at and above 10 ng/mL were required to
produce a significant induction of Arginase-1 expression
and concomitant reduction in iNOS expression in LPS-
stimulated BV2 microglia (Fig. 1w, x). Similarly, main-
taining IL-4 at 10 ng/mL demonstrated that db-cyclic
AMP concentrations at and beyond 0.1 mM could trig-
ger a significant induction of Arginase-1 along with the
parallel inhibition of iNOS expression during the pheno-
type conversion of M1 microglia to M2 (Fig. 1y, z).
Cyclic AMP profoundly modifies cytokine secretion in
microglia stimulated to the M1 phenotype by LPS or TNF-α
The cytokine secretory profile of untreated or resting
(M0), M1 (induced by LPS or TNF-α stimulation), or
M2a (converted from M1 with IL-4 and db-cyclic AMP)
BV2 microglia was investigated in culture supernatants
at 24 h using specific ELISAs for TNF-α, IL-1β, or IP-10.
ELISAs for each of these major pro-inflammatory cy-
tokines were performed from three independent ex-
periments. Compared to M0, the LPS-treated form
showed a significant increase in the levels of TNF-α
(TNF-α, 7.4-fold increase, p < 0.001; Fig. 2a). Simi-
larly, TNF-α stimulation of the cells produced ele-
vated concentrations of IP-10 in the culture
supernatant at 24 h following treatment (IP-10, 4.9-
fold increase, p < 0.001; Fig. 2b). IL-4 addition alone
produced a modest, though significant reduction in
the levels of TNF-α and IP-10 compared to stimu-
lated controls; however, a major abrogation in the
secretion of these cytokines was achieved with db-
cyclic AMP or its combination with IL-4 (Fig. 2a, b).
In contrast, IL-1β production following a 24-h TNF-α
stimulus did not show any significant differences between
the M0, M1, or M2a phenotypes, though M1 microglia
exposed to db-cyclic AMP alone did show significantly en-
hanced levels of IL-1β (1.7-fold increase, p < 0.05) com-
pared to stimulated controls (Fig. 2c).
M1 to M2 conversion of microglia by the synergistic
action of IL-4 and cyclic AMP can be observed at the
single cell level
The synergistic effects of cyclic AMP and IL-4 in regulat-
ing expression of Arginase-1 and iNOS was examined
within single cells of primary cortical microglia challenged
Fig. 1 Synergistic action of cyclic AMP and IL-4 in M1 to M2a phenotypic conversion of microglial cells. In LPS (100 ng/ml)-stimulated BV2 microglia,
combined treatment with db-cyclic AMP (1 mM) and IL-4 (10 ng/ml) beginning at 15 min prior to M1 activation produced dramatic reductions in the
M1 markers (red) iNOS (a, f) and COX-2 (b, g) at 24 h post-stimulus while concurrently increasing M2a markers (red) Arginase-1 (c, h), transglutaminase-
2 (d, i), and RELM-α (e, j). Scale bar = 12 μm. Similarly, conversion of M0 BV2 microglia (k, l) to M1 with TNF-α produced robust iNOS expression (m)
without immunoreactivity for Arginase-1 (n). IL-4 (10 ng/ml) alone produced some expressions of Arginase-1 (p) but did not alter iNOS production (o),
while db-cyclic AMP (1 mM) reduced iNOS and induced little Arginase-1 expression in TNF-α-stimulated microglia (r). Only the simultaneous addition
of IL-4 and db-cyclic AMP to TNF-α-induced M1 microglia produced profound M2a conversion as evidenced by a loss of iNOS (s) and strong Arginase-1
expression (t). Microglial cells are stained with phalloidin-488 (green) to demark the cell morphology, and the nuclei of the cells have been counterstained
with Hoechst (blue). Scale bar= 20 μm. Immunoblotting showed that only the combination of db-cyclic AMP and IL-4 produced a robust induction of
Arginase-1 in M0 or M1 microglia (stimulated with either LPS or TNF-α; u, v). Immunoblotting for Arginase-1 and iNOS in LPS-stimulated BV2 microglia
following their exposure to increasing concentrations of IL-4 (fixed db-cyclic AMP concentration, w, x) or with increasing concentrations of db-cyclic AMP
(fixed IL-4 concentration, y, z) shows the concentrations at which synergistic action is observed in their conversion of microglia from M1 to
M2a. Densitometry values for Arginase-1 and iNOS were normalized to β-actin. Statistical significance indicated at ***p < 0.001, **p < 0.01, or
*p < 0.05 versus LPS-only-treated controls. Results are shown from three independent culture replicates
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iNOS were low in M0 microglia and not significantly dif-
ferent from one another (Fig. 2d–f ), upon TNF-α stimula-
tion, a profound increase in iNOS over Arginase-1 was
observed in single microglial cells (Fig. 2g–i). The expos-
ure of M1 microglia to either IL-4 (Fig. 2j–l) or db-cyclic
AMP (Fig. 2m–o) was not able to reverse the balance of
Arginase-1 to iNOS expression that significantly favored
the later in single cells. In contrast, the concurrent expos-
ure of M1 microglia to IL-4 and db-cyclic AMP switched
the balance of Arginase-1 to iNOS expression to signifi-
cantly favor Arginase-1 (Fig. 2p–r), indicative of an M1 to
M2 phenotype conversion.The cyclic AMP-protein kinase A pathway confers M1 to
Arginase-1+ M2a phenotype conversion in microglia
The main effector pathways downstream of cyclic AMP
are coordinated through PKA and the exchange protein
directly activated by cyclic AMP (EPAC), which have
been shown to regulate often distinct cellular processes
in neural cells [22]. To probe the involvement of PKA
and EPAC in M2a phenotype conversion, selective cyclic
AMP analogs that activate PKA or EPAC were employed
in combination with IL-4 in cultures of primary cortical
microglial cells. Similar to db-cyclic AMP, the PKA-
specific cyclic AMP analogs, dioctanoyl-cyclic AMP, and
6-phenyl-cyclic AMP, but not the EPAC-selective
Fig. 2 (See legend on next page.)
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Fig. 2 M1 to M2a conversion of microglia alters secretory profiles, occurs at the single cell level, and requires PKA, but not EPAC, signaling in the presence
of IL-4. Treatment of M1 (LPS; 100 ng/ml or TNF-α stimulated 10 ng/ml) BV2 microglia with db-cyclic AMP (1 mM) and IL-4 (10 ng/ml) beginning at 15 min
prior to activation produced maximal abrogation of cytokines, TNF-α (a) and IP-10 (b) at 24 h post-stimulus. Levels of IL-1β remained statistically indifferent
between M0, M1, and M2a phenotypes (c), with only db-cyclic AMP alone producing a significant increase over TNF-α stimulated controls. Examination of
primary cortical microglia at the single cell level showed, compared to untreated M0 microglia (d, e), a significant shift in the ratio of Arginase-1 (red) to
iNOS (green) expression, favoring the latter (g–i), occurred when the microglia were induced to the M1 form with TNF-α. The exposure of M1 microglia to
either IL-4 (j–l) or db-cyclic AMP (m–o) independently failed to alter this ratio. In contrast, concurrent use of db-cyclic AMP and IL-4 significantly shifted the
ratio of Arginase-1 to iNOS expression to one favoring the former (p–r), indicative of M1 to M2a phenotypic conversion. Statistical significance indicated at
***p< 0.001 or **p< 0.01 versus iNOS FL intensity/cell. Scale bar= 15 μm. s Immunoblotting for Arginase-1 in BV2 microglia showed little expression in M0-
untreated cells or M1 cells induced with LPS and either untreated or exposed to IL-4. Concurrent delivery of IL-4 with cyclic AMP analogs showed that
those that selectively activated PKA (db-cyclic AMP, 1 mM; dioctanoyl-cyclic AMP, 100 μM; phenyl-cyclic AMP, 100 μM), but not EPAC (CPT-2′O
methyl-cyclic AMP, 100 μM and 8-bromo-2′O methyl-cyclic AMP, 100 μM), induced robust Arginase-1 expression, indicative of M1 to M2a
phenotypic conversion. t Densitometry values for Arginase-1 in untreated and treatment groups normalized to β-actin. The expression of Arginase-1 (red)
and iNOS (green) in primary microglia treated with LPS alone (u1–u2) or in conjunction with IL-4 and cyclic AMP analogs that activate PKA and/or EPAC
(v1–x2), shows the importance of PKA in mediating conversion towards an Arg1+/iNOS- phenotype in the presence of IL-4. Statistical significance indicated
at ***p< 0.001 or *p< 0.05 versus untreated controls or ###p< 0.001 or #p< 0.05 versus LPS-only-treated controls. c–j Immunocytochemical staining of pri-
mary microglia for Arginase-1 (red) and macrosialin (ED1; green) in control and treated microglia showed robust induction of Arginase-1 with PKA-selective,
but not EPAC-selective, cyclic AMP analogs in the presence of LPS and IL-4. Cell nuclei were counterstained with Hoechst (blue). Scale bar= 15 μm. Results
shown from three independent culture replicates
Ghosh et al. Journal of Neuroinflammation  (2016) 13:9 Page 8 of 14analogs, CPT-2′O methyl-cyclic AMP or 8-bromo-2′O
methyl-cyclic AMP, induced a significant increase in
Arginase-1 expression when combined with IL-4 treat-
ment in M1 microglia (Fig. 2s–t). These results were then
confirmed using immunocytochemistry for Arginase-1 in
primary cultures of microglia (Fig. 2u–x). LPS-stimulated
primary microglia exhibited little immunoreactivity for
Arginase-1 and robust expression of macrosialin (ED-1), a
characteristic marker of activated microglia and macro-
phages (Fig. 2u1–u2). Strong Arginase-1 immunoreactivity
was observed in M1 microglia exposed to IL-4 when used
in combination with the PKA activators db-cyclic AMP
(Fig. 2v1–v2) and phenyl-cyclic AMP (Fig. 2w1–w2), but
not with the EPAC-selective cyclic AMP analog CPT-2′O
methyl-cyclic AMP (Fig. 2x1–x2).
Cyclic AMP restores IL-4 mediated deficits of phagocytic
activity in the M2a phenotype
The phagocytic ability of M2a converted microglia fol-
lowing treatment with LPS and IL4, with or without db-
cyclic AMP, was comparatively examined to LPS-
stimulated alone (M1) and M0 (no treatment) microglia
through quantification of their capacity to phagocytose
PE-conjugated latex beads. Compared to untreated cells
(Fig. 3a), LPS stimulation of BV2 microglia to an M1
phenotype enhanced their ability to phagocytose PE-
conjugated beads (3.3-fold higher than untreated, p <
0.001; Fig. 3b, f ). In contrast, IL-4 produced a significant
impairment in the phagocytic capacity of M1-activated
microglia (2.7-fold lower than LPS, p < 0.001; ns com-
pared to untreated, Fig. 3c, f ). Conversely, the addition
of db-cyclic AMP alone significantly increased the
phagocytic activity of the M1 phenotype (Fig. 3d) and
additionally restored the deficits observed in the phago-
cytic properties conferred in IL-4 driven M2a microglia(Fig. 3e, f ), conferring a phagocytic activity significantly
greater than that of LPS stimulation alone (1.4-fold and
1.3-fold higher than LPS, p < 0.01 and p < 0.05, respectively;
Fig. 3f). These results demonstrate that an important role
of classically activated M1 microglia, phagocytosis and deb-
ris clearance, is retained in the converted M2a phenotype.
Elevated levels of cyclic AMP combined with IL4
antagonizes the production of reactive oxygen and
nitrogen species following microglial activation
We examined whether M2a converted microglia, ob-
tained through the combined exposure of M1 microglia
to IL-4 and db-cyclic AMP, produced reactive oxygen
(ROS) and/or nitrogen species (RNS), cytotoxic mole-
cules that are associated with the M1 microglial cell
phenotype. The ability of M1 microglia to produce RNS,
measured by nitrite concentration, was detected based
on the Griess reaction. Compared to untreated controls,
LPS stimulation of BV2 microglia to the M1 form pro-
duced a significant increase in cell nitrite concentration
(1.5-fold increase, p < 0.001; Fig. 3g). Concurrent use of
IL-4 with LPS significantly attenuated this increase
(Fig. 3g). The employment of either db-cyclic AMP
alone or M2a phenotypic conversion with the combin-
ation of IL-4 and db-cyclic AMP, further reduced nitrite
concentrations to levels significantly lower than that of
untreated controls (2.3-fold and 5.9-fold reduction com-
pared to untreated, p < 0.001 for both, respectively;
Fig. 3g). Levels of ROS detected using DCFH-DA
showed that LPS stimulation of BV2 microglia produced
a significant increase in ROS production compared to
untreated controls (1.4-fold increase, p < 0.05; Fig. 3h).
The concomitant use of IL-4 or db-cyclic AMP alone
did not significantly reduce the increase in ROS pro-
duced by LPS stimulation. Only when db-cyclic AMP
Fig. 3 M1 to M2a phenotype conversion of microglia does not perturb their phagocytic function but does reduce the production of reactive species.
a–e The phagocytic capacity of BV2 microglia was assayed by the ability of the cells to phagocytose phycoerythrin (PE)-conjugated latex beads (red) after
treatment with LPS (100 ng/ml) in the presence or the absence of IL-4 (10 ng/ml) and db-cyclic AMP (1 mM) added alone or simultaneously 15 min prior
to activation and incubated for 24 h post-treatment. Co-staining for nuclei (Hoechst, blue) and the cytoplasm (phalloidin-488, green) was employed to
demark cell morphology. Scale bar= 12 μm. f. Quantitative analysis of PE-bead uptake. g, h Measurements of nitrite concentration (g) or reactive oxygen
species (h) in cell lysates from untreated and treated groups were measured at 24 h post-stimulus with conditions inducing the pro-inflammatory or the
anti-inflammatory state as mentioned above. Statistical significance indicated at ***p< 0.001 or *p< 0.05 versus untreated controls or ###p< 0.001, ##p<
0.01, or #p< 0.05 versus LPS-only-treated controls. Results are shown from five independent culture replicates
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M2a phenotype conversion was the LPS-induced gener-
ation of ROS in microglia completely perturbed (1.5-fold
decrease, p < 0.01 compared to LPS stimulation; ns com-
pared to untreated; Fig. 3h).
Acute systemic co-administration of IL4 and cyclic AMP
induces a state of alternative activation in microglia and
macrophages after spinal cord injury
To investigate whether M1 to M2a phenotypic conver-
sion of microglia could be accomplished in vivo using
cyclic AMP elevation and IL-4 supplementation, their
concurrent delivery was investigated after contusive
spinal cord injury (SCI) in two different experimental
paradigms. First, in a rodent model, adult Lewis rats
were subjected to injury and the co-administration of
IL-4 and db-cyclic AMP systemically during the acute
phase (within 15 min) of SCI. Using the prototypical
M2a marker Arginase-1, at 24 h after SCI an increase in
Arginase-1 expression was identified in the total spinal
cord tissue homogenates of the lesion site compared to
naïve controls by immunoblotting (5.9-fold increase
compared to naïve, p < 0.05 Fig. 4a, b); indeed, an in-
crease in both M1 and M2 microglia and macrophage
populations has been reported previously in the acute
phase of SCI [10]. The use of M1 to M2a phenotype
conversion with db-cyclic AMP and IL-4 resulted in asignificant enhancement of Arginase-1 production at
24 h after SCI (11.1-fold increase compared to naïve, p
< 0.01 and p < 0.05 versus SCI; Fig. 4a, b). Histological
examination of tissue sections from the injury epicenter
showed that, compared to SCI controls (Fig. 4c, d), the
combination of db-cyclic AMP and IL-4 after SCI pro-
duced a marked reduction in numbers of Iba1+ (Fig. 4e)
and ED1+ (Fig. 4f) microglia and macrophages within the
lesion site. Co-staining of ED1+ microglia or macrophages
with Arginase-1 revealed that at 24 h after SCI alone, only
a small fraction of ED1+ cells were immunoreactive for
Arginase-1 (Fig. 4d–f; white arrows). In contrast, when
M2a phenotype conversion with db-cyclic AMP and IL-4
was used acutely after SCI, almost all the ED1+ microglia
and macrophages were immunoreactive for Arginase-1
(Fig. 4h–j; white arrows), indicating that they were of the
M2a phenotype. To assess the effects of M2 microglia and
macrophage conversion on the pathological processes of
injury, we assessed at 24 h the generation of total free
ROS/RNS radicals within the lesion site by employing the
fluorogenic probe dichlorodihydrofluorescin DiOxyQ
(DCFH-DiOxyQ), which is a specific ROS/RNS probe
[23]. Compared to SCI controls, the combination of db-
cyclic AMP and IL-4 to induce M1 to M2a phenotypic
conversion produced a significant reduction in the
amount of free radicals generated within the injured spinal
cord (57.6 % reduction, p < 0.05; Fig. 4k).
Fig. 4 M1 to M2a conversion of microglia with cyclic AMP and IL-4 can be used in vivo after SCI and significantly attenuates the production of
tissue-damaging free radicals. a, b Immunoblotting of tissue homogenates from the injury epicenter at 24 h after contusive SCI in rat for the
prototypical M2 marker Arginase-1 shows an increase in expression after SCI that is further potentiated by the co-delivery of db-cyclic AMP
(50 mg/kg) and IL-4 (30 μg/Kg) administered <30 min post-injury. Statistical significance indicated at **p< 0.01 or *p< 0.05 versus uninjured controls or #p
< 0.05 versus SCI only controls. Compared to SCI controls, the administration of db-cAMP and IL-4 produced a dramatic reduction in the numbers of Iba1+
(c, g) and ED1+ (green, d, h) microglia and macrophages within the lesion epicenter at 24 h post-SCI. While few ED1+ microglia and macrophages were
Arginase-1+ (red, white arrows) in SCI-only controls (d, f), almost all ED1+ microglia and macrophages found in db-cyclic AMP and IL-4-treated animals co-
expressed Arginase-1 (h, j; white arrows). The nuclei of the cells have been counterstained with Hoechst (blue). Scale bar = 20 μm. k Compared to SCI only
controls, a dramatic reduction in the total level of free radicals within the injury epicenter was observed with the systemic administration of db-cyclic AMP
and IL-4. Statistical significance indicated at #p< 0.05 versus SCI only controls. Four animals were used in each group. Following contusive SCI in mouse,
compared to injury-only controls (l–n), daily treatment initiating at <30 min post-SCI induction with IL-4 (30 μg/kg) and db-cyclic AMP (50 mg/kg) for seven
consecutive days post-SCI (o–q) increased the number of Isolectin-IB4 positive immune cells (red) that were immunoreactive for Arginase-1 (green) within
the lesion site. The nuclei of the cells have been counterstained with Hoechst (blue). Scale bar= 40 μm. r Quantitative assessment of the numbers of
Isolectin-IB4+ cells immunoreactive for Arginase-1 showed a significant increase with db-cyclic AMP and IL-4 after SCI. Statistical significance indicated at
###p< 0.001 versus SCI-only controls
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moderate SCI using c57/Bl6 mice. These mice received
either SCI alone or SCI with the co-administration of IL-4
and db-cyclic AMP acutely post-SCI and then daily for
7 days. Immunohistochemical analysis of spinal cord tissue
at the lesion site at 7 days post-SCI showed that compared
to SCI controls (Fig. 4l–n), a significant increase in the
number of Isolectin-IB4+ microglia and macrophages im-
munoreactive for Arginase-1 occurred with the concurrent
delivery of IL-4 and db-cyclic AMP (Fig. 4o–q). Arginase-1immunoreactivity at the center of the lesion appeared
largely restricted to Isolectin-IB4+ cells. Quantitative assess-
ment of the number of Isolectin-IB4+ microglia and macro-
phages that co-stained with Arginase-1 after SCI showed a
significant increase with IL-4 and db-cyclic AMP over SCI
controls (3.0-fold increase; p < 0.001; Fig. 4r).
Discussion
Trauma to the CNS produces an intense and chronic re-
action to the injury by resident microglia and infiltrating
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to tissue preservation and a reduction in neurological
deficits [24] or, when specifically enhanced, can produce re-
pair [25]. Recent work has attributed these diverse activities
to the heterogeneity of the microglia and macrophage re-
sponses to injury, with the presence of distinct immuno-
phenotypical populations of these cells providing unique
functional roles within the injury environment [10, 26].
These phenotypes are broadly defined into two forms based
upon gene profiling and proteomics, the classically acti-
vated M1 form and the alternatively activated M2 form,
though it is clear that further work remains in the molecu-
lar identification of distinct microglial cell populations
in vivo that possess different behavioral characteristics.
Though our understanding of the complexity of the
microglia and macrophage responses following injury
requires further experimentation to elucidate how these
different populations alter the injury environment to-
wards one of tissue damage or repair, it does appear
based upon temporal population dynamics within the
lesion milieu that the conversion of one phenotype to
another is possible [10, 27, 28] and that factors present
within the injury microenvironment strongly regulate
the microglia and macrophage phenotypic responses and
function [9, 29, 30]. The dominating role of signals from
the injury milieu in driving the M1 phenotype was
recently demonstrated in studies by Kigerl et al., [10]
where they showed that M2-converted macrophages, in-
duced with IL-4, while retaining their phenotype when
microinjected into the intact spinal cord, were converted
into the M1 state when injected into the injured spinal
cord. Indeed, while both M1 and M2 microglia and mac-
rophages are present within the acutely injured spinal
cord, the M2 response is short-lived, dissipating within
3–7 days after injury [10], pointing to an environment
supportive of only the M1 phenotype [31].
With the injured CNS showing concurrently a dra-
matic and chronic reduction in levels of the important
secondary messenger, cyclic AMP [32], and based upon
the important role that cyclic AMP plays in maintaining
both microglia and monocyte homeostasis to prevent
M1 activation [15, 33], we hypothesized that the eleva-
tion of cyclic AMP would be a pre-requisite to pro-M2
anti-inflammatory cytokine stimulation for a persistent
M2 phenotypical conversion from an M1 activated state.
As shown in the present report, the combination of
cyclic AMP elevation and stimulation with IL-4, but nei-
ther agent alone at the doses employed, was able to con-
vert LPS-activated, M1 microglia to an M2a phenotype
as characterized by a number of specific M1 and M2a
markers. Though further dose-finding studies with the
prototypical M2 inducer IL-4 alone [34–36] may allow
the determination of a concentration of IL-4 that can
achieve a significant induction of M2 markers in thesecell culture systems, it is clear from this work that cyclic
AMP provides a powerful synergism with IL-4 to induce
M1 to M2a microglial conversion where individually
these agents failed to at doses that are physiologically
relevant. We and others have shown that cyclic AMP-
elevating agents, including adenylyl cyclase activators,
phosphodiesterase inhibitors, and synthetic analogs can
retard the classical (M1) activation of microglia or mac-
rophages largely through antagonism of the master tran-
scriptional regulator of inflammation, nuclear factor
kappa B (NF-κB; [11, 33]). In addition, cyclic AMP can
also synergistically act with IL-4 to induce the expres-
sion of M2-regulated genes, such as Arginase-1, by
activating the transcription factor CCAAT/enhancer-
binding protein (C/EBP) [37]; thus, both of these mecha-
nisms are likely important for the interplay of these
signals in promoting persistent M1 to M2 conversion.
According to recent sub-type classification of the M2
phenotype by immunocytochemical markers [9], the
cyclic AMP and IL-4 converted microglia retain the M2a
form; the substitution of IL-4 with other anti-
inflammatory cytokines, such as IL-10 or TGF-β, in con-
junction with cyclic AMP failed to recapitulate this M1
to M2a microglia conversion (data not shown), while IL-
13 produced an analogous response to IL-4 with cyclic
AMP (unpublished data). Functionally, the M2a conver-
sion of M1 microglia with cyclic AMP and IL-4 signifi-
cantly abated their production of pro-inflammatory
cytokines (TNF-α) and chemokines (IP-10) and oxidative
molecules (ROS/RNS), while increasing their phagocytic
function. The production of pro-inflammatory cytokines
and oxidative metabolites are key effectors of M1 microglia
in exacerbating tissue damage after CNS injury [2], while
for M2 microglia, the down-regulation of these inflamma-
tory factors coupled with enhanced phagocytosis and ECM
remodeling are important for their reparative actions [4].
While in the current study, microglial cells treated
with LPS did not exhibit Arginase-1 expression, other
work has shown that LPS can increase Arginase-1 within
microglia in vitro [38] and in vivo [39, 40]. However, in
each of these cases, there was the presence of additional
stimuli or environmental factors that could have altered
the response of microglia to LPS. In work by Lisi and
colleagues [38], LPS stimulation occurred in the pres-
ence of conditioned media from C6 Glioma cells, media
containing growth factors, and cytokines that could have
altered the response to LPS leading to Arginase-1 ex-
pression. Similarly, in a study by Zhang and co-workers
[40], involving a model of Endotoxin-induced uveitis
(EIU), the break-down of the blood-ocular barrier and
the infiltration of leukocytes in the retina following ad-
ministration of LPS may have led to indirect effects on
the microglia from secreted factors from leukocytes [41]
or other glial cells (Muller glia). Secreted factors from
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glia to LPS in their production of Arginase-1. This envir-
onmental difference could also be a reason for the
observed induction of Arginase-1 in cortical microglia
following intraparenchymal injection of LPS in the brain
[40]. Examining how LPS-induced changes in Arginase-
1 expression by microglia may be altered by the presence
of cytokines, growth factors, and other cell types would
shed light on how the signaling pathways downstream of
these factors are integrated in regulating microglial cell
phenotype.
Through the use of PKA- and EPAC-selective cyclic
AMP analogs, we demonstrated the importance of PKA,
but not EPAC, in facilitating M1 to M2a microglia con-
version in the presence of IL-4. Studies have shown that
in LPS activated RAW 264.7 macrophages, the effects of
cyclic AMP in reducing pro-inflammatory cytokineFig. 5 Synergistic immuno-modulatory effects of cyclic AMP and IL-4 in the
(M0) microglia to a pro-inflammatory stimulus, TNF-α or LPS, drives the cel
expression of cytokines and chemokines, such as TNF-α and IP-10, as well a
tissue injury. In addition, the production of tissue reparative and remodelin
contrast, the concurrent exposure of M0 or M1 microglia to IL-4 and cyclic
M2a form. The M2a phenotype exhibits strong expression of ARG-1, TG2, R
pro-inflammatory cytokine and toxic reactive radical production that are as
exposed to IL-4 alone, there is a transition to an intermediate M2a form. Th
some beneficial characteristics of the M2 phenotype, though exhibits impaproduction, a hallmark of the M1 phenotype, is medi-
ated through PKA [42]. Conversely, other work employ-
ing the same macrophage cell model has highlighted a
role for Epac1-mediated Rap1/NFκB signaling in facili-
tating LPS-induced inflammatory responses [43]. While
the use of EPAC and PKA agonists in the current study
at concentrations previously shown to provide sufficient
activation of the target in vitro [44] demonstrate the im-
portance of PKA and not EPAC in M1 to M2a conver-
sion and are in line with previous reports [43] that
suggest the involvement of PKA and not EPAC as being
the downstream mediator of M1 to M2 conversion; the
use of multiple, higher doses of the EPAC agonists
would be needed to completely rule out a role of EPAC
in this process. Nevertheless, if demonstrated, it would
indicate that selective PKA activation rather than broad
cyclic AMP-elevating approaches will be required forM1 to M2a phenotypic conversion of microglia. Subjecting resting
ls to a classically activated (M1) phenotype. The M1 form displays high
s iNOS and free radicles, ROS and RNS, that are key in cytotoxicity and
g enzymes, such as ARG-1, YM1, RELM-α, and TG, are suppressed. In
AMP induces M0/M1 phenotype conversion to a robust reparative
ELM-α, and YM1, an augmented phagocytic ability and the absence of
sociated with the M1 form. When M0- or M1-activated microglia are
e M2a phenotype retains partial characteristics of M1 while acquiring
ired phagocytic function
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effects of EPAC activation.
Not only could M1 to M2a conversion be obtained
phenotypically and functionally with combined cyclic
AMP and IL-4 in vitro in the BV2 microglial cell line
and primary microglia but also in vivo in models of SCI
in rat and mouse. While only a small population of
macrosialin-positive microglia and macrophages within
the injured spinal cord at 24 h after SCI co-expressed
the M2a marker Arginase-1, following the systemic ad-
ministration of cyclic AMP and IL-4, almost all macro-
sialin immunoreactive microglia and macrophages were
also Arginase-1 positive. In addition to promoting M1 to
M2a conversion, this treatment also reduced the total
numbers of macrosialin and iba-1 positive microglia and
macrophages within the injured spinal cord. This reduc-
tion could be produced by an inhibitory effect of cyclic
AMP on macrophage infiltration as observed previously
with cyclic AMP-elevating approaches [20, 45]. A similar
increase in Arginase-1 with cyclic AMP and IL-4 after
SCI was observed also by immunoblotting, and the
in vivo M1 to M2a conversion after SCI was accompan-
ied by a significant reduction in the generation of ROS.
In SCI mice treated with IL-4 and a cyclic AMP analog
for 7 days after injury, a similar significant increase in
Arginase-1+ M2a microglia and macrophages was ob-
served with the combination of agents over injury-only
controls, substantiating this approach as a means to pro-
mote M1 to M2a conversion in vivo after CNS injury as
a putative therapeutic strategy for inducing tissue repair.
Although direct spinal tissue measurements of db-
cAMP and IL-4 were not performed in this study, fol-
lowing SCI, there is acute blood-spinal cord-barrier
(BSCB) disruption to macromolecules for a least 1 week
[46]. Disruption of the BSCB during the 7-day adminis-
tration period of the agents would thus permit systemic-
ally administered IL4 and db-cAMP to readily reach
spinal tissue at the lesion site. Should longer administra-
tion windows be required for achieving an effective
treatment with this approach following SCI, the examin-
ation of spinal cord penetrance would be important to
ensure that adequate levels were present or an alterna-
tive, more direct route for delivery, or small molecule
mimetics/activators of these pathways would be needed.
Conclusions
These studies identify a novel method for M1 to M2a
conversion that could hold great clinical promise as a
therapeutic for CNS injury and disease in altering the
microglia and macrophage responses from one of tissue
injury to one of repair. Undertaking further in vivo work
to optimize dosing of the agents and to determine the
persistence of phenotypic conversion after CNS injury
would pave the way for studies to examine theeffectiveness of this new approach to provide anatomical
protection, neurorepair, and functional benefit. It is also
clear that further characterization of the synergistic
mechanisms involved in M1 to M2 conversion and im-
proved characterization of the relationship between the
molecular profile of distinct microglia phenotypes and
their behavioral responses is needed. As summarized in
Fig. 5, the current work highlights for the first time the
importance of cyclic AMP-PKA signaling in both antag-
onizing M1 microglia activation and inducing the M2a
state in conjunction with anti-inflammatory cytokines,
such as IL-4, to promote M1 to M2a phenotypical
conversion.
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